vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and La Rosa Holdings Corp. (LRHC). Click either name above to swap in a different company.
La Rosa Holdings Corp. is the larger business by last-quarter revenue ($20.2M vs $18.7M, roughly 1.1× CytomX Therapeutics, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -27.4%, a 26.5% gap on every dollar of revenue. On growth, La Rosa Holdings Corp. posted the faster year-over-year revenue change (3.2% vs -25.7%). Over the past eight quarters, La Rosa Holdings Corp.'s revenue compounded faster (72.5% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
V. La Rosa and Sons Macaroni Company was founded in 1914 by Vincenzo La Rosa, a Sicilian immigrant. The company eventually became one of the largest regional brands in the United States producing over 40 varieties of pasta.
CTMX vs LRHC — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $20.2M |
| Net Profit | $-154.0K | $-5.5M |
| Gross Margin | — | 8.4% |
| Operating Margin | -6.9% | -24.7% |
| Net Margin | -0.8% | -27.4% |
| Revenue YoY | -25.7% | 3.2% |
| Net Profit YoY | 97.6% | -125.7% |
| EPS (diluted) | — | $-5.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $20.2M | ||
| Q2 25 | $18.7M | $23.2M | ||
| Q1 25 | $50.9M | $17.5M | ||
| Q4 24 | $38.1M | $17.7M | ||
| Q3 24 | $33.4M | $19.6M | ||
| Q2 24 | $25.1M | $19.1M | ||
| Q1 24 | $41.5M | $13.1M | ||
| Q4 23 | $26.6M | — |
| Q3 25 | — | $-5.5M | ||
| Q2 25 | $-154.0K | $78.4M | ||
| Q1 25 | $23.5M | $-95.7M | ||
| Q4 24 | $18.9M | $-5.1M | ||
| Q3 24 | $5.7M | $-2.5M | ||
| Q2 24 | $-6.5M | $-2.3M | ||
| Q1 24 | $13.8M | $-4.6M | ||
| Q4 23 | $837.0K | — |
| Q3 25 | — | 8.4% | ||
| Q2 25 | — | 8.0% | ||
| Q1 25 | — | 8.8% | ||
| Q4 24 | — | 8.9% | ||
| Q3 24 | — | 8.3% | ||
| Q2 24 | — | 8.3% | ||
| Q1 24 | — | 8.9% | ||
| Q4 23 | — | — |
| Q3 25 | — | -24.7% | ||
| Q2 25 | -6.9% | -10.6% | ||
| Q1 25 | 44.4% | -26.7% | ||
| Q4 24 | 46.4% | -17.1% | ||
| Q3 24 | 12.3% | -8.9% | ||
| Q2 24 | -33.7% | -9.7% | ||
| Q1 24 | 28.1% | -35.0% | ||
| Q4 23 | -2.3% | — |
| Q3 25 | — | -27.4% | ||
| Q2 25 | -0.8% | 337.8% | ||
| Q1 25 | 46.2% | -546.5% | ||
| Q4 24 | 49.6% | -28.7% | ||
| Q3 24 | 17.2% | -12.5% | ||
| Q2 24 | -26.0% | -12.2% | ||
| Q1 24 | 33.3% | -35.1% | ||
| Q4 23 | 3.1% | — |
| Q3 25 | — | $-5.44 | ||
| Q2 25 | — | $15.25 | ||
| Q1 25 | — | $-5.86 | ||
| Q4 24 | — | $28.54 | ||
| Q3 24 | — | $-16.49 | ||
| Q2 24 | — | $-12.49 | ||
| Q1 24 | — | $-0.35 | ||
| Q4 23 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $4.0M |
| Total DebtLower is stronger | — | $642.8K |
| Stockholders' EquityBook value | $119.9M | $1.6M |
| Total Assets | $175.1M | $21.7M |
| Debt / EquityLower = less leverage | — | 0.41× |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $4.0M | ||
| Q2 25 | $49.0M | $5.1M | ||
| Q1 25 | $47.6M | $2.9M | ||
| Q4 24 | $38.1M | $1.4M | ||
| Q3 24 | $40.6M | $1.8M | ||
| Q2 24 | $43.2M | $1.6M | ||
| Q1 24 | $36.2M | $1.1M | ||
| Q4 23 | $17.2M | — |
| Q3 25 | — | $642.8K | ||
| Q2 25 | — | $644.3K | ||
| Q1 25 | — | $645.9K | ||
| Q4 24 | — | $647.6K | ||
| Q3 24 | — | $649.2K | ||
| Q2 24 | — | $650.8K | ||
| Q1 24 | — | $652.4K | ||
| Q4 23 | — | — |
| Q3 25 | — | $1.6M | ||
| Q2 25 | $119.9M | $3.4M | ||
| Q1 25 | $25.0M | $-87.5M | ||
| Q4 24 | $-456.0K | $2.6M | ||
| Q3 24 | $-23.5M | $5.0M | ||
| Q2 24 | $-31.2M | $4.7M | ||
| Q1 24 | $-31.7M | $5.6M | ||
| Q4 23 | $-47.4M | — |
| Q3 25 | — | $21.7M | ||
| Q2 25 | $175.1M | $22.9M | ||
| Q1 25 | $98.5M | $21.0M | ||
| Q4 24 | $120.5M | $19.4M | ||
| Q3 24 | $139.0M | $19.7M | ||
| Q2 24 | $159.2M | $18.7M | ||
| Q1 24 | $184.7M | $16.3M | ||
| Q4 23 | $201.8M | — |
| Q3 25 | — | 0.41× | ||
| Q2 25 | — | 0.19× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.25× | ||
| Q3 24 | — | 0.13× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | — | 0.12× | ||
| Q4 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $-1.3M |
| Free Cash FlowOCF − Capex | $-15.8M | — |
| FCF MarginFCF / Revenue | -84.6% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-1.3M | ||
| Q2 25 | $-15.8M | $-1.4M | ||
| Q1 25 | $-21.0M | $-3.5M | ||
| Q4 24 | $-19.9M | $-1.1M | ||
| Q3 24 | $-20.7M | $-591.6K | ||
| Q2 24 | $-19.5M | $-803.1K | ||
| Q1 24 | $-26.0M | $-538.3K | ||
| Q4 23 | $-22.0M | — |
| Q3 25 | — | — | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.2M | — | ||
| Q4 24 | $-20.0M | — | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.6M | — | ||
| Q1 24 | $-26.2M | — | ||
| Q4 23 | $-22.2M | — |
| Q3 25 | — | — | ||
| Q2 25 | -84.6% | — | ||
| Q1 25 | -41.6% | — | ||
| Q4 24 | -52.5% | — | ||
| Q3 24 | -62.1% | — | ||
| Q2 24 | -78.2% | — | ||
| Q1 24 | -63.1% | — | ||
| Q4 23 | -83.5% | — |
| Q3 25 | — | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.3% | — | ||
| Q4 23 | 1.0% | — |
| Q3 25 | — | — | ||
| Q2 25 | — | -0.02× | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — | ||
| Q4 23 | -26.24× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
LRHC
| Real Estate Residential Brokerage Services | $16.8M | 83% |
| Transferred Over Time | $3.5M | 17% |
